About: A Randomized, Open‐label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Randomized, Open‐label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Randomized, Open‐label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study
Creator	Liu, Yong Luo, Hong Wang, Jin Wang, Ling Chang, Junbiao Cui, Guangying Dong, Lihong Du, Jinfa Hu, Chuansong Li, Qingquan Liang, Lan Pei, Guangzhong Ren, Zhigang Song, Chuanjun Song, Jingchao Song, Wenbin Wang, Haiyu Yang, Shengkun Yu, Wenquan Yu, Zujiang Zeng, Zhaohai Zhu, Yonghui
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID‐19) has spread worldwide. To date, no specific drug for COVID‐19 has been developed. Thus we performed this randomized, open‐label, controlled clinical trial (ChiCTR2000029853) in China. A total of 20 mild and common COVID‐19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatments (control group). The mean times of the first nucleic acid negative conversion (NANC) of 10 patients in the FNC group and 10 patients in the control group were 2.60 (SD 0.97; range 1–4) days and 5.60 (SD 3.06; range 2–13) days, respectively (p = 0.08). The mean times of the first NANC of 4 newly diagnosed subjects in the FNC group and 10 subjects in the control group were 2.50 (SD 1.00; range 2–4) days and 9.80 (SD 4.73; range 3–19) days, respectively (starting from the initial treatment) (p = 0.01). No adverse events occurred in the FNC group, while 3 adverse events occurred in the control group (p = 0.06). The preliminary results showed that FNC treatment in the mild and common COVID‐19 may shorten the NANC time versus standard antiviral treatment. Therefore, clinical trials of FNC treating COVID‐19 with larger sample size are warranted.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1002/advs.202001435
bibo:pmid	32837847
has license	cc-by
sha1sum (hex)	40412ceb23f361c42132c4dd5329f412fbc3a81a
schema:url	https://doi.org/10.1002/advs.202001435
resource representing a document's title	A Randomized, Open‐label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study
has PubMed Central identifier	PMC7404576
has PubMed identifier	32837847
schema:publication	Adv Sci (Weinh)
resource representing a document's body	covid:40412ceb23f361c42132c4dd5329f412fbc3a81a#body_text
is schema:about of	named entity 'antiviral treatment' named entity 'worldwide' named entity 'randomly assigned' named entity 'range' named entity 'CORONAVIRUS DISEASE 2019' named entity 'ASSIGNED' named entity 'TREATMENT' named entity 'patients' named entity 'patients' named entity 'receive' named entity 'warranted' named entity 'days' named entity 'subjects' named entity 'shorten' named entity 'COVID-19' named entity 'initial' named entity 'performed' named entity 'COVID-19' named entity 'COVID-19' named entity 'Randomized' named entity 'control group' named entity 'NANC' named entity 'antiviral' named entity 'open-label' named entity '0.01' named entity 'antiviral treatment' named entity 'control group' named entity 'control group' named entity 'adverse events' named entity 'protected by copyright' named entity 'Open-label' named entity 'COVID' named entity 'times' named entity 'fever' named entity 'CT scan' named entity 'nucleoside' named entity 'adverse reactions' named entity 'nucleic acid testing' named entity 'DNA polymerases' named entity 'nucleic acid' named entity 'adverse events' named entity 'Kaplan-Meier' named entity 'COVID-19' named entity 'prognosis' named entity 'China' named entity 'genus' named entity 'adverse events' named entity 'nucleoside' named entity 'control group' named entity 'vital signs' named entity 'respiratory symptoms' named entity 'white blood cells' named entity '28 days' named entity 'lung' named entity 'control group' named entity 'nucleic acid testing' named entity 'tested positive' named entity 'clinical trial' named entity 'nucleoside analogs' named entity 'antiviral drugs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software